Evidence map›Paper›PMID 41974474›Full record

ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2026

Subsequent primary neoplasm risk among survivors of cancer in adolescence and young adulthood: a population-based study from Alberta, Canada.

Arafat Ul Alam, Devan Tchir, Sarah McKillop, Natalie Logie, Tyler Cavanaugh, Paul C Nathan, Kathleen A Reynolds, Miranda M Fidler-Benaoudia

Abstract read
In one paragraph

Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arafat Ul AlamDepartment of Oncology (Alam, Logie, Fidler-Benaoudia), University of Calgary; Department of Cancer Epidemiology and Prevention Research (Alam, Fidler-Benaoudia) and Cancer Research & Analytics (Tchir), Cancer Care Alberta, Calgary, Alta.; Pediatric Hematology-Oncology (McKillop), Stollery Children's Hospital; Department of Pediatrics (McKillop), University of Alberta, Edmonton, Alta.; Department of Radiation Therapy (Logie), Cancer Care Alberta, Calgary, Alta.; patient partner (Cavanaugh); Division of Hematology/Oncology (Nathan), Hospital for Sick Children and Institute of Health Policy, Management and Evaluation (Nathan), University of Toronto, Toronto, Ont.; Long-Term Survivor's Clinic (Reynolds), Alberta Children's Hospital; Department of Community Health Sciences (Fidler-Benaoudia), University of Calgary, Calgary, Alta.
Devan TchirDepartment of Oncology (Alam, Logie, Fidler-Benaoudia), University of Calgary; Department of Cancer Epidemiology and Prevention Research (Alam, Fidler-Benaoudia) and Cancer Research & Analytics (Tchir), Cancer Care Alberta, Calgary, Alta.; Pediatric Hematology-Oncology (McKillop), Stollery Children's Hospital; Department of Pediatrics (McKillop), University of Alberta, Edmonton, Alta.; Department of Radiation Therapy (Logie), Cancer Care Alberta, Calgary, Alta.; patient partner (Cavanaugh); Division of Hematology/Oncology (Nathan), Hospital for Sick Children and Institute of Health Policy, Management and Evaluation (Nathan), University of Toronto, Toronto, Ont.; Long-Term Survivor's Clinic (Reynolds), Alberta Children's Hospital; Department of Community Health Sciences (Fidler-Benaoudia), University of Calgary, Calgary, Alta.
Sarah McKillopDepartment of Oncology (Alam, Logie, Fidler-Benaoudia), University of Calgary; Department of Cancer Epidemiology and Prevention Research (Alam, Fidler-Benaoudia) and Cancer Research & Analytics (Tchir), Cancer Care Alberta, Calgary, Alta.; Pediatric Hematology-Oncology (McKillop), Stollery Children's Hospital; Department of Pediatrics (McKillop), University of Alberta, Edmonton, Alta.; Department of Radiation Therapy (Logie), Cancer Care Alberta, Calgary, Alta.; patient partner (Cavanaugh); Division of Hematology/Oncology (Nathan), Hospital for Sick Children and Institute of Health Policy, Management and Evaluation (Nathan), University of Toronto, Toronto, Ont.; Long-Term Survivor's Clinic (Reynolds), Alberta Children's Hospital; Department of Community Health Sciences (Fidler-Benaoudia), University of Calgary, Calgary, Alta.
Natalie LogieDepartment of Oncology (Alam, Logie, Fidler-Benaoudia), University of Calgary; Department of Cancer Epidemiology and Prevention Research (Alam, Fidler-Benaoudia) and Cancer Research & Analytics (Tchir), Cancer Care Alberta, Calgary, Alta.; Pediatric Hematology-Oncology (McKillop), Stollery Children's Hospital; Department of Pediatrics (McKillop), University of Alberta, Edmonton, Alta.; Department of Radiation Therapy (Logie), Cancer Care Alberta, Calgary, Alta.; patient partner (Cavanaugh); Division of Hematology/Oncology (Nathan), Hospital for Sick Children and Institute of Health Policy, Management and Evaluation (Nathan), University of Toronto, Toronto, Ont.; Long-Term Survivor's Clinic (Reynolds), Alberta Children's Hospital; Department of Community Health Sciences (Fidler-Benaoudia), University of Calgary, Calgary, Alta.
Tyler CavanaughDepartment of Oncology (Alam, Logie, Fidler-Benaoudia), University of Calgary; Department of Cancer Epidemiology and Prevention Research (Alam, Fidler-Benaoudia) and Cancer Research & Analytics (Tchir), Cancer Care Alberta, Calgary, Alta.; Pediatric Hematology-Oncology (McKillop), Stollery Children's Hospital; Department of Pediatrics (McKillop), University of Alberta, Edmonton, Alta.; Department of Radiation Therapy (Logie), Cancer Care Alberta, Calgary, Alta.; patient partner (Cavanaugh); Division of Hematology/Oncology (Nathan), Hospital for Sick Children and Institute of Health Policy, Management and Evaluation (Nathan), University of Toronto, Toronto, Ont.; Long-Term Survivor's Clinic (Reynolds), Alberta Children's Hospital; Department of Community Health Sciences (Fidler-Benaoudia), University of Calgary, Calgary, Alta.
Paul C NathanDepartment of Oncology (Alam, Logie, Fidler-Benaoudia), University of Calgary; Department of Cancer Epidemiology and Prevention Research (Alam, Fidler-Benaoudia) and Cancer Research & Analytics (Tchir), Cancer Care Alberta, Calgary, Alta.; Pediatric Hematology-Oncology (McKillop), Stollery Children's Hospital; Department of Pediatrics (McKillop), University of Alberta, Edmonton, Alta.; Department of Radiation Therapy (Logie), Cancer Care Alberta, Calgary, Alta.; patient partner (Cavanaugh); Division of Hematology/Oncology (Nathan), Hospital for Sick Children and Institute of Health Policy, Management and Evaluation (Nathan), University of Toronto, Toronto, Ont.; Long-Term Survivor's Clinic (Reynolds), Alberta Children's Hospital; Department of Community Health Sciences (Fidler-Benaoudia), University of Calgary, Calgary, Alta.
Kathleen A ReynoldsDepartment of Oncology (Alam, Logie, Fidler-Benaoudia), University of Calgary; Department of Cancer Epidemiology and Prevention Research (Alam, Fidler-Benaoudia) and Cancer Research & Analytics (Tchir), Cancer Care Alberta, Calgary, Alta.; Pediatric Hematology-Oncology (McKillop), Stollery Children's Hospital; Department of Pediatrics (McKillop), University of Alberta, Edmonton, Alta.; Department of Radiation Therapy (Logie), Cancer Care Alberta, Calgary, Alta.; patient partner (Cavanaugh); Division of Hematology/Oncology (Nathan), Hospital for Sick Children and Institute of Health Policy, Management and Evaluation (Nathan), University of Toronto, Toronto, Ont.; Long-Term Survivor's Clinic (Reynolds), Alberta Children's Hospital; Department of Community Health Sciences (Fidler-Benaoudia), University of Calgary, Calgary, Alta.
Miranda M Fidler-BenaoudiaDepartment of Oncology (Alam, Logie, Fidler-Benaoudia), University of Calgary; Department of Cancer Epidemiology and Prevention Research (Alam, Fidler-Benaoudia) and Cancer Research & Analytics (Tchir), Cancer Care Alberta, Calgary, Alta.; Pediatric Hematology-Oncology (McKillop), Stollery Children's Hospital; Department of Pediatrics (McKillop), University of Alberta, Edmonton, Alta.; Department of Radiation Therapy (Logie), Cancer Care Alberta, Calgary, Alta.; patient partner (Cavanaugh); Division of Hematology/Oncology (Nathan), Hospital for Sick Children and Institute of Health Policy, Management and Evaluation (Nathan), University of Toronto, Toronto, Ont.; Long-Term Survivor's Clinic (Reynolds), Alberta Children's Hospital; Department of Community Health Sciences (Fidler-Benaoudia), University of Calgary, Calgary, Alta. miranda.fidler-benaoudia@albertahealthservices.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurvivors of cancer in adolescence and young adulthood are at increased risk for subsequent primary neoplasms, but studies using Canadian data are limited. We sought to quantify the risk of subsequent primary neoplasms among survivors of cancer in adolescence and young adulthood in Alberta, Canada.

methodsThe Alberta Adolescent and Young Adult Cancer Survivor Study is a retrospective, population-based cohort of people aged 15 to 39 years with a neoplasm first diagnosed between 1983 and 2017. We assessed risks of subsequent primary neoplasms overall and after 5-year survival, calculated as standardized incidence ratios (SIRs) and absolute excess risks (AERs) per 10 000 person-years, compared with expected general population rates, with up to 30 years of follow-up.

resultsAmong 24 459 people who had cancer in adolescence and young adulthood, 1442 had subsequent primary neoplasms, 1129 of which occurred after 5-year survival. The risk of subsequent primary neoplasm overall and after 5-year survival was similar (SIR 2.2, 95% confidence interval [CI] 2.1 to 2.4 v. 2.0, 95% CI 1.9 to 2.2; AER 31.7, 95% CI 28.7 to 34.6 v. 35.7, 95% CI 31.6 to 39.8 per 10 000 person-years). Most subsequent primary neoplasms were breast, digestive, hematopoietic, or respiratory cancers. After 5-year survival, the 30-year cumulative incidence of a subsequent primary neoplasm was 17.7% (95% CI 16.5% to 18.9%), with incidence highest among survivors of cancers of the oral cavity, lip, or pharynx (28.9%, 95% CI 18.9% to 39.6%), breast cancer (27.3%, 95% CI 23.7% to 30.9%), colon cancer (23.5%, 95% CI 14.2% to 34.1%), and Hodgkin lymphoma (22.7%, 95% CI 18.2% to 27.6%).

interpretationSurvivors of cancer in adolescence and young adulthood are at increased risk for nearly all types of subsequent primary neoplasms assessed. Early, risk-based screening may be warranted, particularly for screen-detectable cancers for which risks are greatest.

Indexed as

Cancer SurvivorsNeoplasmsNeoplasms, Second PrimaryAdolescentAdultAlbertaFemaleHumansIncidenceMaleRetrospective StudiesRisk FactorsYoung Adult

Identifiers

PMID41974474
PMCPMC13082848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.